Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.

Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G.

Blood. 2002 Aug 15;100(4):1168-71.

2.

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G.

Blood. 2001 Sep 1;98(5):1614-5.

3.

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G.

Blood Coagul Fibrinolysis. 2002 Apr;13(3):187-92.

PMID:
11943931
4.

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.

Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G.

Clin Lymphoma. 2003 Jun;4(1):32-5.

PMID:
12837152
5.

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G.

J Clin Oncol. 2003 Jul 15;21(14):2732-9. Erratum in: J Clin Oncol.2008 Apr 20;26(12): 2066.

PMID:
12860952
6.

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.

Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.

Eur J Haematol. 2007 Apr;78(4):297-302. Epub 2007 Feb 5.

PMID:
17286608
7.

Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.

Badros A, Morris C, Zangari M, Barlogie B, Tricot G.

Leuk Lymphoma. 2002 Jun;43(6):1267-71.

PMID:
12152995
8.

Thalidomide and dexamethasone: therapy for multiple myeloma.

Kumar S, Rajkumar SV.

Expert Rev Anticancer Ther. 2005 Oct;5(5):759-66. Review.

PMID:
16221046
9.

Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.

Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M.

Blood Coagul Fibrinolysis. 2009 Jul;20(5):337-9. doi: 10.1097/MBC.0b013e32832b27e6.

PMID:
19367157
10.

A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.

Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC.

Cancer. 2015 Oct 15;121(20):3622-30. doi: 10.1002/cncr.29533. Epub 2015 Jul 6.

11.

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.

Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G.

Br J Haematol. 2004 Sep;126(5):715-21.

PMID:
15327525
12.

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.

Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, Mitterer M, Südhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J.

Br J Haematol. 2003 Aug;122(4):607-16.

PMID:
12899716
13.

Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.

Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M.

Cancer. 2007 Aug 15;110(4):824-9.

14.

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K.

Semin Hematol. 2003 Oct;40(4 Suppl 4):3-7. Review.

PMID:
15015890
16.

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.

Haematologica. 2005 Dec;90(12):1650-4.

17.

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.

Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M, Valdrè L, Palareti G, Masini L, Tura S, Baccarani M.

Blood. 2002 Sep 15;100(6):2272-3. No abstract available.

18.

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.

Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL.

Br J Haematol. 2006 Jan;132(2):155-61.

PMID:
16398649
19.

Thalidomide and dexamethasone for resistant multiple myeloma.

Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R.

Br J Haematol. 2003 Jun;121(5):768-71.

PMID:
12780791
20.

Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?

Jimenez-Zepeda VH, Domínguez-Martínez VJ.

Eur J Haematol. 2006 Sep;77(3):239-44. Epub 2006 Jul 19.

PMID:
16856924

Supplemental Content

Support Center